Page last updated: 2024-11-12

seletracetam

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Seletracetam: Antiepileptic Agent; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9942725
CHEMBL ID3918017
CHEBI ID188602
SCHEMBL ID387920
MeSH IDM0508882

Synonyms (26)

Synonym
seletracetam
ucb-44212
357336-74-4
D05817
seletracetam (usan/inn)
CHEBI:188602
(2s)-2-[(4s)-4-(2,2-diluoroethenyl)-2-oxopyrrolidin-1-yl]butanamide
rfr2ch3qzk ,
ucb 44212
seletracetam [usan:inn]
1-pyrrolidineacetamide, 4-(2,2-difluoroethenyl)-alpha-ethyl-2-oxo-, (alphas,4s)-
unii-rfr2ch3qzk
(2s)-2-((4s)-4-(2,2-difluoroethenyl)-2-oxopyrrolidin-1-yl)butanamide
seletracetam [inn]
seletracetam [usan]
DB05885
SCHEMBL387920
CHEMBL3918017
DTXSID30905079
(s)-2-((s)-4-(2,2-difluorovinyl)-2-oxopyrrolidin-1-yl)butanamide
HY-119810
CS-0078059
MS-23326
(2s)-2-[(4s)-4-(2,2-difluoroethenyl)-2-oxopyrrolidin-1-yl]butanamide
anwpenapcifdsz-rqjhmyqmsa-n
AKOS040742623

Research Excerpts

Overview

Seletracetam is a pyrrolidone derivative with a one-log-unit higher affinity for the synaptic vesicle protein 2A (SV2A) than levetiracetam.

ExcerptReferenceRelevance
"Seletracetam is a pyrrolidone derivative with a one-log-unit higher affinity for the synaptic vesicle protein 2A (SV2A) than levetiracetam (Keppra). "( Profile of the new pyrrolidone derivative seletracetam (ucb 44212) in animal models of epilepsy.
Kenda, B; Klitgaard, H; Löscher, W; Margineanu, DG; Matagne, A; Michel, P; Potschka, H, 2009
)
2.06

Bioavailability

ExcerptReferenceRelevance
" Initial studies in humans demonstrated first-order monocompartmental kinetics with a half-life of 8 h and an oral bioavailability of >90%."( Seletracetam (UCB 44212).
Bennett, B; Cornet, M; Leonard, M; Matagne, A; Meeus, MA; Michel, P; Toublanc, N, 2007
)
1.78
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
organonitrogen compoundAny heteroorganic entity containing at least one carbon-nitrogen bond.
organooxygen compoundAn organochalcogen compound containing at least one carbon-oxygen bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (55.56)29.6817
2010's3 (33.33)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 115.67

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index115.67 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index206.92 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (115.67)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (22.22%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (77.78%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]